AFP: A Drug Target / Disease Biomarker (G174)

Target Name: AFP

NCBI ID: G174

Content of Review Report on AFP Target / Biomarker

AFP

AFP: A Drug Target / Disease Biomarker

AFP, short for alpha-fetoprotegerin, is a protein produced by the liver that is often used as a marker for the presence of cancer in humans. The protein is derived from the alpha-fetoprotegerin gene, which is located on chromosome 21.

One of the key characteristics of AFP is its ability to bind to a protein called CD73, which is a transmembrane protein that is expressed in various tissues throughout the body. When CD73 is bound to a surface on a cell, it triggers a signaling cascade that results in the production of activated T cells, which are a type of immune cell that play a critical role in fighting off infections and cancer.

In addition to its role in immune function, AFP has also been shown to play a key role in the development and progression of certain types of cancer. For example, studies have shown that high levels of AFP in the blood are associated with an increased risk of pancreatic cancer, as well as with other types of cancer, such as breast, ovarian, and prostate cancer.

Despite these promising findings, the field of AFP research is still in its infancy. There is currently no FDA-approved drug target for AFP, and there are no approved biomarkers for use in cancer diagnosis or treatment.

One potential approach to developing a drug target for AFP is to target the CD73 protein itself. This would involve using small molecules or antibodies to inhibit the activity of CD73, which would in turn reduce the production of activated T cells and decrease the level of AFP in the blood.

Another potential approach to developing a drug target for AFP is to target the liver, where the protein is produced. This could involve using drugs or toxins to damage the liver, which would reduce the production of AFP and decrease its levels in the blood.

While further research is needed to fully understand the role of AFP in cancer and to develop effective drug targets, the potential benefits of targeting this protein make it an attractive target for future research. If successful, these treatments could provide new ways to diagnose and treat a range of cancers.

Protein Name: Alpha Fetoprotein

Functions: Binds copper, nickel, and fatty acids as well as, and bilirubin less well than, serum albumin. Only a small percentage (less than 2%) of the human AFP shows estrogen-binding properties

The "AFP Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about AFP comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets